VCYT Stock: Price, Earnings History and SEC Filings
Veracyte, Inc. (VCYT) last traded at $50.01, down 4.14% on the latest session and up 8.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.37 against an analyst estimate of $0.29, a beat of 27.6%.
$50.01 -4.14%
1 month+8.62%
52-week high$60.91
52-week low$29.46
Volume1.02M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VCYT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $0.37 | $0.29 | +27.59% |
| Mar 2026 | May 5, 2026 | $0.37 | $0.23 | +60.87% |
| Dec 2025 | Feb 25, 2026 | $0.40 | $0.28 | +42.86% |
| Sep 2025 | Nov 4, 2025 | $0.38 | $0.19 | +100.00% |
VCYT beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for VCYT
SEC filing data is not available right now. You can search for VCYT on SEC EDGAR.
VCYT news
- 4 Medical Stocks With a Healthy Shot at Q3 Earnings BeatsOct 30, 2026 · finance.yahoo.com
- Veracyte to Participate in Upcoming Investor ConferencesOct 29, 2026 · finance.yahoo.com
- Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseOct 29, 2026 · finance.yahoo.com
- Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Oct 28, 2026 · finance.yahoo.com
- Clinical Trial Data Might Change The Case For Investing In Veracyte Stock (VCYT)Oct 28, 2026 · finance.yahoo.com
- Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerOct 23, 2026 · finance.yahoo.com
- Veracyte: Strong Diagnostic Growth And Improving MarginsOct 22, 2026 · seekingalpha.com
- Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Oct 21, 2026 · finance.yahoo.com
About Veracyte, Inc.
Veracyte, Inc. (VCYT) is a US-listed public company on Nasdaq.